Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 25, 2007

Advancement of Respiratory Disease Drug Triggers $1M Payment to Pharmacopeia

  • Schering-Plough’s initiation of human trials prompted a $1 million payment to Pharmacopeia. The compound, PS948115, identified through the firms’ partnership, is being evaluated as a treatment for respiratory disease.

    “The Schering-Plough collaboration continues to yield very attractive therapeutic candidates,” points out Les Browne, Ph.D., president and CEO of Pharmacopeia. In March the companies reported Phase I evaluation of an anti-inflammatory compound and in April they selected another candidate for preclinical evaluation.

    Schering-Plough is solely responsible for further development and commercialization. Pharmacopeia is eligible to receive additional milestone payments depending on development success and royalties on resulting products.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »